NWLF also will offer consultations regarding strategies of bringing products to the market in Eastern Europe as a primary market entry point, as well as strategies to grow existing markets. All of the above services will be available for OTC and prescription drugs and devices. NWLF will provide the expertise of its team of advisors to support the newly planned marketing efforts.

Wieslaw J. Bochenek, M.D., Ph.D., F.A.C.P. president of New Life Scientific, Inc. commented, "We believe that our position in Eastern Europe will allow us to offer a wider range of services than simply as a contract research organization. In meetings with various companies interested in our clinical trial capabilities, we have learned that these same companies are eager to pursue the research and marketing abilities we are developing."